National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
Funding Amount
Up to $499,999
Deadline
January 7, 2027
74 days left
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- For-profit businesses
- Tribal organizations
- County governments
- City & township governments
- Nonprofits without 501(c)(3) status
- State governments
- Nonprofits (501(c)(3))
- School districts
Other requirements
- Territory or Possession.
Overview
Through this Notice of Funding Opportunity, the National Cancer Institute (NCI) seeks research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: PAR-25-081
- Total Funding: $499,999
- Instrument: grant
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Focus Areas & Funding Uses
Fields of Work
- Cancer
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
October 30, 2026
GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)
National Institutes of Health
Amount
$2,000,000 total
Deadline
October 30, 2026
GREGoRi Innovation Projects (U01 Clinical Trial Optional)
National Institutes of Health
Amount
$3 – $500K
Deadline
October 30, 2026
GREGoRi Technology Integration Center (U01, Clinical Trials Optional)
National Institutes of Health
Amount
$3,000,000 total
Deadline
October 30, 2026
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
November 2, 2026
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
November 2, 2026
Ready to apply for National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required). Now let's win it.